Crescent Biopharma (NASDAQ:CBIO) Stock Rating Lowered by Wall Street Zen

Crescent Biopharma (NASDAQ:CBIO) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other analysts have also recently issued reports about the company. Jefferies Financial Group initiated coverage on Crescent Biopharma in a research report on Monday, August 25th. They issued a “buy” rating and a $26.00 price objective for the company. Weiss Ratings restated a “sell (e-)” rating on shares of Crescent Biopharma in a research note on Monday, December 1st. Stifel Nicolaus set a $32.00 price target on Crescent Biopharma in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Crescent Biopharma in a research report on Wednesday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $26.40.

Crescent Biopharma Stock Up 0.6%

Crescent Biopharma stock opened at $13.07 on Friday. The business’s 50-day moving average price is $12.72. The firm has a market cap of $181.54 million, a price-to-earnings ratio of -0.62 and a beta of 1.32. Crescent Biopharma has a fifty-two week low of $9.81 and a fifty-two week high of $37.00.

Crescent Biopharma (NASDAQ:CBIO) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.26). Sell-side analysts anticipate that Crescent Biopharma will post -0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC acquired a new stake in shares of Crescent Biopharma during the 2nd quarter worth approximately $4,520,000. Jefferies Financial Group Inc. bought a new stake in Crescent Biopharma during the second quarter worth $437,000. Perceptive Advisors LLC acquired a new stake in shares of Crescent Biopharma in the 2nd quarter valued at $7,322,000. Commodore Capital LP acquired a new stake in shares of Crescent Biopharma in the 2nd quarter valued at $7,322,000. Finally, Soleus Capital Management L.P. acquired a new position in shares of Crescent Biopharma during the 2nd quarter worth $6,456,000. Institutional investors own 75.19% of the company’s stock.

About Crescent Biopharma

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.